Pharmacist Perspectives Beyond HIV Viral Suppression

CE

Beyond Viral Suppression: Expert Strategies to Improve Patient Outcomes—Pharmacist Perspectives

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: June 10, 2024

Expiration: June 09, 2025

Lucas Hill
Lucas Hill, PharmD, AAHIVP, BCACP
Bernadette Jakeman
Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

For a patient with stable viral suppression and a good CD4 count, what is your most common reason for discussing with your patient whether they are on the best ART regimen for them?

2.

Case 1: Background



  • 42-yr-old man with HIV diagnosed 1 yr ago

  • Has been taking BIC/FTC/TAF since diagnosis

  • Adherent to ART

    • Taking a pill every day reminds him of HIV



  • No other PMH or chronic medications


Should an ART switch be considered for this person?

3.

Case 3: Background



  • 52-yr-old man diagnosed with HIV in 1995

  • Sexual history: has sex with men

  • 1995-2012: depression, substance use, and intermittent housing insecurity with viremia on combination NRTI therapy, then  NRTIs combined with anchor drugs  (IDV, NFV, NVP, and EFV)

  • 2013-2015: intermittent suppression on DRV/RTV + RAL + MVC; poor adherence

  • 2015 genotype: pan resistance to NRTIs, NNRTIs, and PIs; N155H to INSTIs; dual/mixed tropic

    • Switched to DRV/RTV BID + FTC/TAF + DTG BID with improved adherence



  • Currently: CD4+ 390 cells/mm3 and HIV-1 RNA <50 c/mL

  • Treated for gonorrhea 6 mo ago; no other comorbidities or comedications

For this person with viral suppression on an optimized ART regimen, what other intervention(s) could be recommended?